Clinical features, diagnostic challenges, and management strategies in checkpoint inhibitor-related pneumonitis
Sarah Chuzi,1 Fabio Tavora,2 Marcelo Cruz,3 Ricardo Costa,3 Young Kwang Chae,3 Benedito A Carneiro,3 Francis J Giles3 1Department of Medicine, Feinberg School of Medicine, Northwestern University, Chicago, IL, USA; 2Argos Laboratory, Messejana Heart and Lung Hospital, Fortaleza, Brazil; 3Development...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Dove Medical Press
2017-06-01
|
| Series: | Cancer Management and Research |
| Subjects: | |
| Online Access: | https://www.dovepress.com/clinical-features-diagnostic-challenges-and-management-strategies-in-c-peer-reviewed-article-CMAR |
| _version_ | 1819265893838880768 |
|---|---|
| author | Chuzi S Tavora F Cruz M Costa R Chae YK Carneiro BA Giles FJ |
| author_facet | Chuzi S Tavora F Cruz M Costa R Chae YK Carneiro BA Giles FJ |
| author_sort | Chuzi S |
| collection | DOAJ |
| description | Sarah Chuzi,1 Fabio Tavora,2 Marcelo Cruz,3 Ricardo Costa,3 Young Kwang Chae,3 Benedito A Carneiro,3 Francis J Giles3 1Department of Medicine, Feinberg School of Medicine, Northwestern University, Chicago, IL, USA; 2Argos Laboratory, Messejana Heart and Lung Hospital, Fortaleza, Brazil; 3Developmental Therapeutics Program, Division of Hematology/Oncology, Feinberg School of Medicine, Northwestern University, Chicago, IL, USA Abstract: Immune checkpoint inhibitors, including cytotoxic T-lymphocyte antigen 4 (CTLA-4) and programmed cell death-1 (PD-1) inhibitors, represent an effective treatment modality for multiple malignancies. Despite the exciting clinical benefits, checkpoint inhibition is associated with a series of immune-related adverse events (irAEs), many of which can be life-threatening and result in significant treatment delays. Pneumonitis is an adverse event of special interest as it led to treatment-related deaths in early clinical trials. This review summarizes the incidence of pneumonitis during treatment with the different checkpoint inhibitors and discusses the prognostic significance of tumor type. The wide range of clinical, radiographic, and histologic characteristics of checkpoint inhibitor-related pneumonitis is reviewed and followed by guidance on the different management strategies. Keywords: immune checkpoint inhibitors, pneumonitis, anti-PD-1, anti-CTLA-4, immune-related adverse event |
| first_indexed | 2024-12-23T20:52:37Z |
| format | Article |
| id | doaj.art-128eeb726d274710a123fd57cfe6b526 |
| institution | Directory Open Access Journal |
| issn | 1179-1322 |
| language | English |
| last_indexed | 2024-12-23T20:52:37Z |
| publishDate | 2017-06-01 |
| publisher | Dove Medical Press |
| record_format | Article |
| series | Cancer Management and Research |
| spelling | doaj.art-128eeb726d274710a123fd57cfe6b5262022-12-21T17:31:37ZengDove Medical PressCancer Management and Research1179-13222017-06-01Volume 920721333289Clinical features, diagnostic challenges, and management strategies in checkpoint inhibitor-related pneumonitisChuzi STavora FCruz MCosta RChae YKCarneiro BAGiles FJSarah Chuzi,1 Fabio Tavora,2 Marcelo Cruz,3 Ricardo Costa,3 Young Kwang Chae,3 Benedito A Carneiro,3 Francis J Giles3 1Department of Medicine, Feinberg School of Medicine, Northwestern University, Chicago, IL, USA; 2Argos Laboratory, Messejana Heart and Lung Hospital, Fortaleza, Brazil; 3Developmental Therapeutics Program, Division of Hematology/Oncology, Feinberg School of Medicine, Northwestern University, Chicago, IL, USA Abstract: Immune checkpoint inhibitors, including cytotoxic T-lymphocyte antigen 4 (CTLA-4) and programmed cell death-1 (PD-1) inhibitors, represent an effective treatment modality for multiple malignancies. Despite the exciting clinical benefits, checkpoint inhibition is associated with a series of immune-related adverse events (irAEs), many of which can be life-threatening and result in significant treatment delays. Pneumonitis is an adverse event of special interest as it led to treatment-related deaths in early clinical trials. This review summarizes the incidence of pneumonitis during treatment with the different checkpoint inhibitors and discusses the prognostic significance of tumor type. The wide range of clinical, radiographic, and histologic characteristics of checkpoint inhibitor-related pneumonitis is reviewed and followed by guidance on the different management strategies. Keywords: immune checkpoint inhibitors, pneumonitis, anti-PD-1, anti-CTLA-4, immune-related adverse eventhttps://www.dovepress.com/clinical-features-diagnostic-challenges-and-management-strategies-in-c-peer-reviewed-article-CMARimmune checkpoint inhibitorspneumonitisanti-PD-1anti-CTLA-4immune-related adverse event |
| spellingShingle | Chuzi S Tavora F Cruz M Costa R Chae YK Carneiro BA Giles FJ Clinical features, diagnostic challenges, and management strategies in checkpoint inhibitor-related pneumonitis Cancer Management and Research immune checkpoint inhibitors pneumonitis anti-PD-1 anti-CTLA-4 immune-related adverse event |
| title | Clinical features, diagnostic challenges, and management strategies in checkpoint inhibitor-related pneumonitis |
| title_full | Clinical features, diagnostic challenges, and management strategies in checkpoint inhibitor-related pneumonitis |
| title_fullStr | Clinical features, diagnostic challenges, and management strategies in checkpoint inhibitor-related pneumonitis |
| title_full_unstemmed | Clinical features, diagnostic challenges, and management strategies in checkpoint inhibitor-related pneumonitis |
| title_short | Clinical features, diagnostic challenges, and management strategies in checkpoint inhibitor-related pneumonitis |
| title_sort | clinical features diagnostic challenges and management strategies in checkpoint inhibitor related pneumonitis |
| topic | immune checkpoint inhibitors pneumonitis anti-PD-1 anti-CTLA-4 immune-related adverse event |
| url | https://www.dovepress.com/clinical-features-diagnostic-challenges-and-management-strategies-in-c-peer-reviewed-article-CMAR |
| work_keys_str_mv | AT chuzis clinicalfeaturesdiagnosticchallengesandmanagementstrategiesincheckpointinhibitorrelatedpneumonitis AT tavoraf clinicalfeaturesdiagnosticchallengesandmanagementstrategiesincheckpointinhibitorrelatedpneumonitis AT cruzm clinicalfeaturesdiagnosticchallengesandmanagementstrategiesincheckpointinhibitorrelatedpneumonitis AT costar clinicalfeaturesdiagnosticchallengesandmanagementstrategiesincheckpointinhibitorrelatedpneumonitis AT chaeyk clinicalfeaturesdiagnosticchallengesandmanagementstrategiesincheckpointinhibitorrelatedpneumonitis AT carneiroba clinicalfeaturesdiagnosticchallengesandmanagementstrategiesincheckpointinhibitorrelatedpneumonitis AT gilesfj clinicalfeaturesdiagnosticchallengesandmanagementstrategiesincheckpointinhibitorrelatedpneumonitis |